Increased macrophage-colony stimulating factor levels in neonates with perinatal complications

Ikeno, Kazuhide; Koike, Kenichi; Fukuromoto, Takashi; Shimizu, Tohru; Nagatomo, Midori; Korniyama, Atsushi

doi:10.1016/0378-3782(96)01766-5

Cited by 14 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…M-CSF-induced macrophages produce a large amount of IL-10, but a minimal level of IL-12 (21). Compared with GM-CSF, M-CSF is constitutively detected in human serum and is greatly elevated in immune suppressive conditions like pregnancy, neonatal cord blood, and tumors (22)(23)(24). Loss of M-CSF induces pregnancy blocking and abortion when M-CSF-deficient mice are mated to nonsyngeneic mice strains (25).…”

Section: Endritic Cells Are Professional Apcs and Play A Pivotal Romentioning

confidence: 99%

“…Study of DCs in cord blood may help to elucidate ways to decrease the incidence of GVHD in cord blood, as well as in bone marrow transplantation. Physiologically, cord blood monocytes might have a greater chance to be exposed to M-CSF and IL-4 because higher serum levels of M-CSF have been detected in cord blood than in adult blood (23,24) and pregnancy is associated with a skewed Th2 cytokine (IL-4) profile (48). Therefore, we chose to use cord blood to study whether M-CSF, in combination with IL-4 could induce cord blood monocyte differentiation into suppressive DCs.…”

Section: Endritic Cells Are Professional Apcs and Play A Pivotal Romentioning

confidence: 99%

See 1 more Smart Citation

Macrophage Colony-Stimulating Factor Drives Cord Blood Monocyte Differentiation into IL-10highIL-12absent Dendritic Cells with Tolerogenic Potential

Kim

Broxmeyer

2005

The Journal of Immunology

View full text Add to dashboard Cite

Immature dendritic cells (DCs) induce tolerance and mature DCs induce inflammatory immune responses. However, the likelihood of maturation of immature DCs in vivo limits its potential application for suppression of unwanted immune reactions in vivo. The aim of this study was to generate DCs with anti-inflammatory properties in both the immature and mature states. GM-CSF combined with IL-4 drives monocyte differentiation into DCs. As M-CSF is a critical cytokine in development of the monocytic lineage and its level is dramatically elevated in immunosuppressive conditions, we investigated whether M-CSF could replace GM-CSF and generate DCs with distinct functions from umbilical cord blood monocytes. Highly purified umbilical cord blood monocytes cultured with M-CSF and IL-4, in a GM-CSF-independent fashion, differentiated into IL-10highIL-12absent cells with a DC phenotype (termed M-DC). Single time stimulation with immature DCs (both M-DCs and DCs) derived from cord blood induced hyporesponsive and regulatory CD4+ T cells. In contrast to mature DCs, mature M-DCs induced decreased Th1 differentiation and proliferation of naive CD4+ T cells in both primary and secondary allogeneic MLR and showed tolerogenic potential. These results demonstrate an unrecognized role for M-CSF in alternative differentiation of monocytes into anti-inflammatory M-DCs and suggest that M-CSF-induced DCs may be of use for suppressing unwanted immune responses.

show abstract

Section: Endritic Cells Are Professional Apcs and Play A Pivotal Romentioning

confidence: 99%

Section: Endritic Cells Are Professional Apcs and Play A Pivotal Romentioning

confidence: 99%

Macrophage Colony-Stimulating Factor Drives Cord Blood Monocyte Differentiation into IL-10highIL-12absent Dendritic Cells with Tolerogenic Potential

Kim

Broxmeyer

2005

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…[16][17][18] M-CSF is elevated during pregnancy and in cord blood. 19,20 Taken together, the above information offers possible explanations for low incidence and severity of GVHD in cord blood transplantation. In this context, our observation suggests that M-CSF administration after UR-BMT might decrease severity of chronic GVHD, through induction of certain types of macrophages and DCs.…”

Section: Discussionmentioning

confidence: 99%

M-CSF attenuates severity of chronic GVHD after unrelated BMT

Kimura

Sato

Akiyama

et al. 2011

Bone Marrow Transplant

View full text Add to dashboard Cite

To study the effects of M-CSF administration on longterm outcomes of unrelated BMT, we retrospectively analyzed data from patients transplanted through the Japan Marrow Donor Program. We obtained data from 54 patients who received M-CSF just after BMT and 500 patients who did not receive M-CSF or G-CSF acted as controls. There were no significant differences between the two cohorts with respect to OS, acute GVHD or relapse. Although the incidence of chronic GVHD was comparable between the two groups, extensive chronic GVHD was observed significantly less often in the M-CSF cohort than in the control group. Multivariate analysis identified M-CSF as a significant factor for attenuating extensive chronic GVHD (relative risk: 0.73; 95% confidence interval: 0.55-0.94; P ¼ 0.012). We also found the same results in matched-pair analysis. Our observation suggests the potential for clinical use of M-CSF to dampen severe chronic GVHD.

show abstract

“…Recently, an immunoregulatory property of this cytokine has also been suggested. M-CSF is constitutively present in human serum and is greatly elevated in immune suppressive conditions (Bartocci et al, 1986;Ikeno et al, 1996), probably playing a role in maintaining maternal tolerance toward embryos (Piccinni et al, 1997). M-CSF not only has the ability to drive monocyte differentiation into DCs with tolerogenic potential (Li et al, 2005), but also inhibits DC differentiation from CD34 + progenitors by downregulation of CD1a and upregulation of CD14 expression (Menetrier-Caux et al, 1998).…”

Section: Discussionmentioning

confidence: 99%

“…Subsequent investigations revealed that M-CSF has a variety of functions such as inhibiting production of proinflammatory cytokines (Kojima et al, 1996;Nishina et al, 2004), and M-CSF levels dramatically increase in immunosuppressive conditions (Bartocci et al, 1986;Ikeno et al, 1996;Saito et al, 1992). M-CSF-stimulated macrophages produce a large amount of IL-10, but a minimal level of IL-12 (Smith et al, 1998).…”

Section: Introductionmentioning

confidence: 99%

Antigen presenting cells treated in vitro by macrophage colony-stimulating factor and autoantigen protect mice from autoimmunity

Guan

Zhao

et al. 2007

Journal of Neuroimmunology

View full text Add to dashboard Cite

Macrophage colony-stimulating factor (M-CSF) is a critical cytokine in the development of monocytic lineage and may have immunoregulatory properties. Here we show that peritoneal antigen presenting cells (APCs) treated with M-CSF produced decreased levels of proinflammatory cytokines IFN-γ, TNF-α and IL-12. These APCs treated with M-CSF + autoantigen peptide significantly suppressed antigen-specific T cell proliferation, induced regulatory CD4 + and CD8 + T cells in vitro and in vivo, and significantly suppressed experimental autoimmune encephalomyelitis (EAE). Thus, in vitro treatment of APCs with M-CSF + autoantigen can be a novel therapeutic option for autoimmune diseases.

show abstract

Increased macrophage-colony stimulating factor levels in neonates with perinatal complications

Cited by 14 publications

References 8 publications

Macrophage Colony-Stimulating Factor Drives Cord Blood Monocyte Differentiation into IL-10highIL-12absent Dendritic Cells with Tolerogenic Potential

Macrophage Colony-Stimulating Factor Drives Cord Blood Monocyte Differentiation into IL-10highIL-12absent Dendritic Cells with Tolerogenic Potential

M-CSF attenuates severity of chronic GVHD after unrelated BMT

Antigen presenting cells treated in vitro by macrophage colony-stimulating factor and autoantigen protect mice from autoimmunity

Contact Info

Product

Resources

About